Paroxysmal Nocturnal Hemoglobinuria Resources
Roundtable Highlights Unmet Needs, Economic Burden Associated with PNH
Richard Stefanacci, DO, MGH, MBA, AGSF, CMD, an experienced moderator with managed markets expertise, moderated a virtual roundtable discussion focused on the patient, provider, and payer perspective on paroxysmal nocturnal hemoglobinuria (PNH). The panel included Elise, a patient with PNH who is receiving treatment; Jamie Koprivnikar, MD, a hematologist-oncologist experienced with PNH diagnosis and management; and Michael Jacobs, RPh, an experienced managed care expert with experience across employers, pharmacy benefit managers, and health plans. During a three-part series, the panel addresses the difficulties in diagnosing such a rare disease, the unmet needs for PNH, the economic impact associated with PNH for both patients and payers, and more.
This program is sponsored by Apellis Pharmaceuticals, Inc. The views and opinions expressed in these videos are those of the participants/speakers. Every patient's experience with PNH is unique. Coverage and reimbursement depends on the patient’s health plan and the contract between the healthcare provider and the patient's health plan. Third-party insurers’ coverage policies vary and are updated routinely. The participants in this video have been compensated by Apellis for their participation in this video.